Metreleptin for metabolic disorders associated with generalized or partial lipodystrophy

Expert Review of Endocrinology and Metabolism

Volumn 9, Issue 3, 2014, Pages 205-212

  Simha, Vinaya ^a  

^a MAYO CLINIC   (United States)

Author keywords

Diabetes mellitus; Hypertriglyceridemia; Insulin resistance; Leptin therapy; Lipodystrophy; Metreleptin; Steatohepatitis

Indexed keywords

GLUCOSE; METRELEPTIN;

ADVERSE DRUG REACTION; ARTICLE; CONGENITAL GENERALIZED LIPODYSTROPHY; DIABETES MELLITUS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSLIPIDEMIA; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPODYSTROPHY; METABOLIC DISORDER; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL;

EID: 84899067628     PISSN: 17446651     EISSN: 17448417     Source Type: Journal    
DOI: 10.1586/17446651.2014.894877     Document Type: Article

References (47)

1. Garg A. Clinical review: lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab 2011;96(11): 3313-25
2. Chan JL, Oral EA. Clinical classification and treatment of congenital and acquired lipodystrophy. Endocr Pract 2010;16(2): 310-23
3. Capeau J, Magre J, Lascols O, et al. Diseases of adipose tissue: genetic and acquired lipodystrophies. Biochem Soc Trans 2005;33(Pt 5):1073-7 (Pubitemid 41659116)
4. Moon HS, Dalamaga M, Kim SY, et al. Leptin?s role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals. Endocr Rev 2013; 34(3):377-412
5. Vantyghem MC, Balavoine AS, Douillard C, et al. How to diagnose a lipodystrophy syndrome. Ann Endocrinol (Paris) 2012; 73(3):170-89
6. Krahmer N, Farese RV Jr, Walther TC. Balancing the fat: lipid droplets and human disease. EMBO Mol Med 2013;5(7):905-15
7. Simha V, Garg A. Phenotypic heterogeneity in body fat distribution in patients with congenital generalized lipodystrophy caused by mutations in the AGPAT2 or seipin genes. J Clin Endocrinol Metab 2003; 88(11):5433-7 (Pubitemid 37452750)
8. Agarwal AK, Simha V, Oral EA, et al. Phenotypic and genetic heterogeneity in congenital generalized lipodystrophy. J Clin Endocrinol Metab 2003;88(10):4840-7 (Pubitemid 37357534)
9. Haque WA, Shimomura I, Matsuzawa Y, Garg A. Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab 2002;87(5):2395
10. Misra A, Garg A. Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature. Medicine (Baltimore) 2003;82(2):129-46 (Pubitemid 36331644)
11. Misra A, Peethambaram A, Garg A. Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature. Medicine (Baltimore) 2004;83(1):18-34 (Pubitemid 38124853)
12. Handelsman Y, Oral EA, Bloomgarden ZT, et al. The clinical approach to the detection of lipodystrophy - an AACE consensus statement. Endocr Pract 2013;19(1):107-16
13. Rother KI, Brown RJ. Novel forms of lipodystrophy: why should we care? Diabetes Care 2013;36(8):2142-5
14. Bingham A, Mamyrova G, Rother KI, et al. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine (Baltimore) 2008;87(2):70-86 (Pubitemid 351416773)
15. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005;352(1):48-62 (Pubitemid 40075680)
16. Gavrilova O, Marcus-Samuels B, Graham D, et al. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest 2000;105(3):271-8 (Pubitemid 30094446)
17. Colombo C, Cutson JJ, Yamauchi T, et al. Transplantation of adipose tissue lacking leptin is unable to reverse the metabolic abnormalities associated with lipoatrophy. Diabetes 2002;51(9):2727-33 (Pubitemid 34970925)
18. Shimomura I, Hammer RE, Ikemoto S, et al. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999;401(6748):73-6
19. Oral EA, Simha V, Ruiz E, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002;346(8): 570-8 (Pubitemid 34438818)
20. Chan JL, Wong SL, Orlova C, et al. Pharmacokinetics of recombinant methionyl human leptin after subcutaneous administration: variation of concentrationdependent parameters according to assay. J Clin Endocrinol Metab 2007;92(6): 2307-11 (Pubitemid 46997138)
21. Chou K, Perry CM. Metreleptin: first global approval. Drugs 2013;73(9):989-97
22. Bristol Myers Squibb Press release. FDA Advisory Committee Votes on Investigational Medicine Metreleptin. Available from: http://news.bms.com/ pressrelease/ rd-news/fda-advisory-committeevotes- investigational-medicine- metreleptin [Last accessed 11 December 2013]
23. Javor ED, Cochran EK, Musso C, et al. Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes 2005;54(7):1994-2002 (Pubitemid 40911261)
24. Chan JL, Lutz K, Cochran E, et al. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. Endocr Pract 2011;17(6):922-32
25. Ebihara K, Kusakabe T, Hirata M, et al. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J Clin Endocrinol Metab 2007;92(2):532-41
26. Javor ED, Moran SA, Young JR, et al. Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy. J Clin Endocrinol Metab 2004;89(7):3199-207 (Pubitemid 38951884)
27. Beltrand J, Beregszaszi M, Chevenne D, et al. Metabolic correction induced by leptin replacement treatment in young children with Berardinelli-Seip congenital lipoatrophy. Pediatrics 2007;120(2):e291-6 (Pubitemid 47219478)
28. Kamran F, Rother KI, Cochran E, et al. Consequences of stopping and restarting leptin in an adolescent with lipodystrophy. Horm Res Paediatr 2012;78(5-6):320-5
29. Simha V, Szczepaniak LS, Wagner AJ, et al. Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy. Diabetes Care 2003;26(1):30-5 (Pubitemid 36928991)
30. Petersen KF, Oral EA, Dufour S, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 2002;109(10): 1345-50 (Pubitemid 34546899)
31. Javor ED, Ghany MG, Cochran EK, et al. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology 2005;41(4):753-60 (Pubitemid 40462937)
32. Safar Zadeh E, Lungu AO, Cochran EK, et al. The liver diseases of lipodystrophy: the long-term effect of leptin treatment. J Hepatol 2013;59(1):131-7
33. Casey SP, Lokan J, Testro A, et al. Post-liver transplant leptin results in resolution of severe recurrence of lipodystrophy-associated nonalcoholic steatohepatitis. Am J Transplant 2013; 13(11):3031-4
34. Simha V, Subramanyam L, Szczepaniak L, et al. Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety. J Clin Endocrinol Metab 2012;97(3):785-92
35. Park JY, Javor ED, Cochran EK, et al. Long-term efficacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophy. Metabolism 2007;56(4): 508-16 (Pubitemid 46427848)
36. Lee JH, Chan JL, Sourlas E, et al. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J Clin Endocrinol Metab 2006;91(7):2605-11 (Pubitemid 44024625)
37. Mulligan K, Khatami H, Schwarz JM, et al. The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia. J Clin Endocrinol Metab 2009;94(4):1137-44
38. Magkos F, Brennan A, Sweeney L, et al. Leptin replacement improves postprandial glycemia and insulin sensitivity in human immunodeficiency virus-infected lipoatrophic men treated with pioglitazone: a pilot study. Metabolism 2011;60(7): 1045-9
39. Sekhar RV, Jahoor F, Iyer D, et al. Leptin replacement therapy does not improve the abnormal lipid kinetics of hypoleptinemic patients with HIV-associated lipodystrophy syndrome. Metabolism 2012;61(10): 1395-403
40. McDuffie JR, Riggs PA, Calis KA, et al. Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency. J Clin Endocrinol Metab 2004;89(9):4258-63 (Pubitemid 39244422)
41. Aotani D, Ebihara K, Sawamoto N, et al. Functional magnetic resonance imaging analysis of food-related brain activity in patients with lipodystrophy undergoing leptin replacement therapy. J Clin Endocrinol Metab 2012;97(10):3663-71
42. Unger RH, Scherer PE. Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicity. Trends Endocrinol Metab 2010;21(6):345-52
43. Miyamoto L, Ebihara K, Kusakabe T, et al. Leptin activates hepatic 5?-AMP-activated protein kinase through sympathetic nervous system and alpha1-adrenergic receptor: a potential mechanism for improvement of fatty liver in lipodystrophy by leptin. J Biol Chem 2012;287(48):40441-7
44. Moran SA, Patten N, Young JR, et al. Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy. Metabolism 2004; 53(4):513-19 (Pubitemid 38419197)
45. Vadacca M, Margiotta DP, Navarini L, Afeltra A. Leptin in immuno-rheumatological diseases. Cell Mol Immunol 2011;8(3): 203-12
46. Amylin Pharmaceuticals. Myalept (metreleptin for injection): FDA Endocrinologic and Metabolic Drugs advisory committee meeting. Available from: www.fda.gov/downloads/Advisory Committees/CommitteesMeetingMaterials/ Drugs/EndocrinologicandMetabolicDrugs AdvisoryCommittee/UCM377928.pdf [Last accessed December 2013]
47. Beltrand J, Lahlou N, Le Charpentier T, et al. Resistance to leptin-replacement therapy in Berardinelli-Seip congenital lipodystrophy: an immunological origin. Eur J Endocrinol 2010;162(6):1083-91